Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 251 Consumers Rd Suite 1105 NORTH YORK ON M2J 4R3 |
Tel: | N/A |
Website: | https://aptose.com |
IR: | See website |
Key People | ||
William Glenn Rice Chairman of the Board, President, Chief Executive Officer | Fletcher Payne Chief Financial Officer, Senior Vice President, Chief Business Officer | Rafael Bejar Senior Vice President, Chief Medical Officer | Philippe Ledru Senior Vice President, Chief Commercial Officer |
Business Overview |
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. |
Financial Overview |
For the fiscal year ended 31 December 2023, Aptose Biosciences Inc revenues was not reported. Net loss increased 22% to $51.2M. Higher net loss reflects General and administrative excluding sal increase of 16% to $13.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$6.80 to -$7.58. |
Employees: | 35 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $22.61M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$70.76M as of Dec 31, 2023 |
Net annual income (TTM): | -$69.32M as of Dec 31, 2023 |
Free cash flow (TTM): | -$60.37M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 15,717,701 as of Mar 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |